Clinical Trial: Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis

Brief Summary: Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.

Detailed Summary:
Sponsor: NanoBio Corporation

Current Primary Outcome: Time to healing as assessed by the subject.

Original Primary Outcome: Same as current

Current Secondary Outcome: Percent of subjects with healing by days 3, 4,and 5 as assessed by the subject.

Original Secondary Outcome: Same as current

Information By: NanoBio Corporation

Dates:
Date Received: March 26, 2007
Date Started: February 2007
Date Completion:
Last Updated: May 28, 2008
Last Verified: May 2008